Therapies
The Science
About us
Investors
News

Hit enter to search or ESC to close

Alterity Therapeutics AAN Presentation 5 May 2019

May 6, 2019May 9, 2019 Alterity Therapeutics

Alterity Therapeutics AAN Presentation 5 May 2019 Download

Post navigation

Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting

Alterity Therapeutics commences US investor meetings following positive clinical data

Related Posts

Prana Completes Phase 2 Huntington Disease Trial with PBT2

October 6, 2013

Prana commences research collaboration with Takeda for the treatment of Parkinson’s disease gastrointestinal neuropathology

July 18, 2017

Professor Rudy Tanzi Appointed Prana’s Chief Scientific Advisor

July 17, 2013

Leave a Reply Cancel reply

Your email address will not be published.Required fields are marked *

Save my name, email, and website in this browser for the next time I comment.

Recent Posts

Alterity Therapeutics commences US investor meetings following positive clinical data
Alterity Therapeutics AAN Presentation 5 May 2019
Initial data for Alterity Therapeutics Phase 1 clinical trial released at American Academy of Neurology Annual Meeting
Alterity Therapeutics presents at the American Academy of Neurology Annual Meeting
Alterity Therapeutics Investor Presentation

Recent Comments

Archives

Archives

Categories

Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065